人呼吸道合胞体病毒疫苗的研究进展  

Progress in research on human respiratory syncytial virus vaccine

作　　者：刘建东 张静飞(综述)[1] 刘建凯[1] 郑海发(审校)[1] LIU Jian-dong;ZHANG Jing-fei;LIU Jian-kai;ZHENG Hai-fa(Beijing Minhai Biotechnology Co.Ltd,Beijing Engineering Technology Research Center for New Conjugate Vaccine,Beijing 102600,China)

机构地区：[1]北京民海生物科技有限公司,结合疫苗新技术研究北京市重点实验室,北京102600

出　　处：《中国生物制品学杂志》2021年第2期244-248,共5页Chinese Journal of Biologicals

基　　金：北京博士后工作经费资助项目(2018-zz-040)。

摘　　要：人呼吸道合胞体病毒(respiratory syncytial virus,RSV)是导致全球婴幼儿细支气管炎及肺炎的主要致病原,造成严重的社会负担。目前还无上市预防RSV感染的疫苗。随着科技的不断发展,研究者已研发了许多不同类型的RSV疫苗,包括弱毒活疫苗、嵌合体疫苗、亚单位疫苗、病毒样颗粒疫苗及纳米颗粒疫苗。本文就RSV免疫逃逸机制及其疫苗的研究进展作一综述。Human respiratory syncytial virus(RSV) is a global leading cause of severe respiratory disease and hospitalization in infants,which causes serious social burden. At present,there is no a liscenced vaccine to prevent RSV infection. With the development of technology,various types of RSV vaccines have been deve-loped,including live attenuated vaccine,chimeric vaccine,subunit vaccine,virus-like particle vaccine and nanoparticle vaccine. This paper reviews the progress in the research on immune escape mechanism of RSV and vaccines against the viurs.

关 键 词：人呼吸道合胞体病毒 嵌合体疫苗 亚单位疫苗 纳米颗粒疫苗 

分 类 号：R186+.3[医药卫生—流行病学]